Monitor for future IND-enabling study initiation and larger-scale manufacturing progress. Any upcoming financing will likely be dilutive given small market cap ($7M). Watch for replication of results in GLP or large-animal studies.
TCRT drugs
TCRT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $3.32entry
- T+1 · 9mo ago +0.90%α +1.82% · $3.35
- T+5 · 8mo ago +9.94%α +11.15% · $3.65
- T+20 · 8mo ago −15.06%α −7.12% · $2.82
- T+60 · 6mo ago −26.20%α −35.53% · $2.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alaunos Therapeutics released early non-GLP preclinical data from two diet-induced obesity (DIO) mouse studies showing that its lead drug candidate, ALN1003, produced dose-dependent body weight loss, favorable body composition changes, reduced liver weight, and improved metabolic biomarkers. While the results are encouraging for a non-hormonal obesity treatment, the data are preliminary and subject to limitations, including potential confounding from reduced food and water intake in treated mice.
Key Facts
- ALN1003 showed up to -12.9% mean body weight change vs control (p<0.0001) in DIO mice after 34 days
- Liver weight reduced by up to 55% (high dose group, p<0.01) and liver enzymes (ALT, AST, ALP) improved
- High-dose group had 197 mg/dL glucose vs 320 mg/dL in controls (p<0.0001), and lower total cholesterol
- Drug was generally well tolerated, though mild hypolocomotion and dehydration in high-dose mice were observed
- Company has $1.9M cash as of Sept 30, 2025, with runway into Q2 2026; additional financing planned
Financial Impact
No immediate financial impact; preclinical stage with no revenue or earnings. Cash runway extends to Q2 2026 with $1.9M, but dilutive financing likely needed.
Risk Factors
- Preclinical mouse data may not translate to humans
- Behavioral avoidance of medicated water may confound efficacy interpretation
- Cash runway ends in Q2 2026; high risk of dilutive financing
- Early-stage biotech with no clinical data or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247189 |
Track record
14 reports on TCRT
2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.36% at T+60 after the Apr 15, 2026 report. 4 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago S-3 Bearish 6/10 Entry $1.63 Now $1.60 +1.84% settles Dec 14
- Oct 23, 202624d ago 8-K Bullish 5/10 Entry $2.13 Now $1.60 −24.88% settles Nov 23
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $3.04 Now $1.60 −47.37% settles Nov 19
- Oct 15, 20264w ago SC 13D/A Neutral 6/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
- Oct 15, 20264w ago SC 13D Neutral 5/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
- Oct 13, 20264w ago Press Release Bullish 8/10 Entry $3.03 to $1.67 Now $1.60 −47.19% ▼ −44.88% −41.21% vs SPY
- Oct 13, 20264w ago 8-K Bullish 8/10 Entry $3.03 to $1.71 Now $1.60 −47.19% ▼ −43.56% −39.95% vs SPY
- Oct 9, 20265w ago 8-K Bearish 7/10 Entry $1.05 to $1.67 Now $1.60 −52.38% ▼ −59.05% −62.31% vs SPY
- Sep 18, 20268w ago Press Release Bearish 5/10 Entry $1.20 to $2.63 Now $1.60 −33.33% ▼ −119.17% −118.96% vs SPY
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $1.60 to $2.18 Now $1.60 +0.00% ▲ +36.25% +34.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers